AIM · AIM ImmunoTech Inc. · Documents

$0.15 +0.00 (+0.13%) At close · Nov 12

Market Cap

$5.93M

39.92M

Volume · Nov 12 377.23K Avg daily vol (3M) 4.39M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

2024

Apr 19

Registration statement S-1

Registration statement

Apr 1

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $202K ▲ 43.3% Net loss $28.96M Diluted EPS -$0.60

Feb 20

Current report 8-K Events of Feb 16

Entered into a material agreement, New debt or off-balance-sheet obligation

Feb 9

Current report 8-K Events of Feb 8

Regulation FD disclosure

Jan 25

Current report 8-K

Regulation FD disclosure

Jan 10

Current report 8-K

Regulation FD disclosure

Jan 10

Current report 8-K Events of Jan 5

Shareholder vote results

2023

Dec 29

Proxy statement DEFA14A

Proxy statement

Nov 28

Proxy statement DEFA14A

Proxy statement

Nov 20

Proxy statement DEFA14A

Proxy statement

Nov 20

Proxy statement DEFA14A

Proxy statement

Nov 15

Current report 8-K

Regulation FD disclosure

Nov 14

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $46K ▲ 119.0% Net loss $7.82M Diluted EPS -$0.16

Nov 8

Current report 8-K

Regulation FD disclosure

Nov 8

Proxy statement DEFA14A

Proxy statement

Nov 7

Proxy statement DEFA14A

Proxy statement

Sep 29

Current report 8-K Events of Sep 28

Entered into a material agreement

Sep 22

Current report 8-K

Regulation FD disclosure

Aug 23

Current report 8-K

Regulation FD disclosure

Aug 23

Proxy statement DEFA14A

Proxy statement

Aug 15

Current report 8-K

Regulation FD disclosure

Aug 14

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $42K ▲ 40.0% Net loss $4.91M Diluted EPS -$0.10

Jul 10

Current report 8-K

Regulation FD disclosure

Jun 27

Current report 8-K

Regulation FD disclosure

May 30

Current report 8-K Events of May 22

Entered into a material agreement

May 15

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $49K ▲ 48.5% Net loss $3.66M

Apr 19

Current report 8-K

Entered into a material agreement

Apr 7

Current report 8-K Events of Apr 4

Entered into a material agreement

Mar 31

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $141K ▲ 4.4% Net loss $19.45M

Mar 30

Current report 8-K Events of Mar 28

Director or officer change, or executive pay

Mar 16

Current report 8-K Events of Mar 15

Regulation FD disclosure

Mar 13

Current report 8-K Events of Mar 10

Regulation FD disclosure

Mar 8

Current report 8-K

Regulation FD disclosure

Mar 6

Current report 8-K

Regulation FD disclosure

Feb 24

Current report 8-K Events of Feb 23

Regulation FD disclosure

Feb 10

Current report 8-K Events of Feb 9

Other events

Feb 6

Current report 8-K

Regulation FD disclosure

Jan 17

Current report 8-K Events of Jan 13

Entered into a material agreement

2022

Nov 14

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $21K ▼ 36.4% Net loss $6.39M

Nov 9

Current report 8-K Events of Nov 3

Shareholder vote results

Nov 3

Proxy statement DEFA14A

Proxy statement

Oct 31

Proxy statement DEFA14A

Proxy statement

Oct 27

Proxy statement DEFA14A

Proxy statement

Oct 26

Proxy statement DEFA14A

Proxy statement

Oct 13

Proxy statement DEFA14A

Proxy statement

Oct 12

Proxy statement DEFA14A

Proxy statement

Sep 26

Proxy statement DEFA14A

Proxy statement

Sep 21

Proxy statement DEFR14A

Proxy statement

Sep 20

Proxy statement DEFA14A

Proxy statement

Sep 9

Current report 8-K

Regulation FD disclosure

Showing 101–150 of 226 documents

Key facts CIK 946644 CUSIP 00901B303 13F (30d) 14 filings 12 filers Visit website Investor relations